3981-65-5

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 504-63-2 trimethyleneglycol 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 627-30-5 1-chloro-3-hydroxypropane 
• 627-18-9 1-bromo-3-propanol 

Downstream Products

• 863888-27-1 2-tert-butyl-4-chloro-5-[4-(3-fluoropropoxy)benzyloxy]-3-(2H)-pyridazinone 
• 863888-26-0 toluene-4-sulfonic acid 3-[4-(1-tert-5 butyl-5-chloro-6-oxo-1,6-dihydropyridazin-4-yloxymethyl)phenoxy]propyl ester 
• 863888-25-9 2-tert-butyl-4-chloro-5-[4-(3-hydroxypropoxy)benzyloxy]-3-(2H)-pyridazinone 
• 863888-24-8 2-tert-butyl-4-chloro-5-(4-(3-(tert-butyl-dimethylsilyloxy)propoxy)benzyloxy)-3-(2H)-pyridazinone 
• 863888-23-7 {4-[3-(tert-butyldimethylsilanyloxy)propoxy]phenyl}methanol 
• 863888-22-6 4-[3-(tert-butyldimethylsilanyloxy)propoxy]benzoic acid methyl ester 
• 902755-95-7 (R)-(-)-1-methylheptyl 4'-[4-(3-hydroxypropyloxy)benzoyloxy]biphenyl-4-carboxylate 
• 46350-87-2 4-(3-hydroxypropyloxy)benzoic acid 
• 72155-09-0 3-propionic acid 

Relevant academic research and scientific papers

Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications

The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a

Semiheterogeneous Dual Nickel/Photocatalytic (Thio)etherification Using Carbon Nitrides

A carbon nitride material can be combined with homogeneous nickel catalysts for light-mediated cross-couplings of aryl bromides with alcohols under mild conditions. The metal-free heterogeneous semiconductor is fully recyclable and couples a broad range of electron-poor aryl bromides with primary and secondary alcohols as well as water. The application for intramolecular reactions and the synthesis of active pharmaceutical ingredients was demonstrated. The catalytic protocol is applicable for the coupling of aryl iodides with thiols as well.

Contrast agents for applications including perfusion imaging

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.

Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers

A series of fluorinated pyridazinone derivatives with IC50 values ranging from 8 to 4000 nM for the mitochondrial complex 1 (MC1) have been prepared. Structure-activity relationship (SAR) assessment indicated preference of the fluorine label to be incorporated on an alkyl side chain rather than directly on the pyridazinone moiety. Tissue distribution studies of a series of analogues ([18F] 22-28) in Sprague-Dawley (SD) rats identified [ 18F]27 as the most promising radiotracer with high uptake in cardiac tissue (3.41%ID/g; 30 min post injection) in addition to favorable heart to nontarget organ distribution ratios. MicroPET images of SD rats and nonhuman primates after [18F]27 administration allowed easy assessment of the myocardium through 60 min with minimal lung or liver interference.

Examination of the interlayer strength of smectic liquid crystals through the study of partially fluorinated and branched fluorinated end-groups

Through the incorporation of partially fluorinated and branched fluorinated end-groups of ferroelectric liquid crystals we aimed to examine the effects on physico-chemical structures and properties, and electrical switching behaviour for a family of compo

Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold

We report the discovery of novel histamine H3 receptor antagonists based on 4-[(1H-imidazol-4-yl)methyl]piperidine. The most potent compounds in the series (e.g., 7) result from the attachment of a substituted aniline amide to the main pharmaco

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Polymerizable compound, polymerizable liquid crystal composition containing the same, and optically anisotropic medium made from the composition

A polymerizable compound represented by formula (I): wherein Q1 and Q2 each independently represent a hydrogen atom or a methyl group; p and q each independently represent an integer of 2 to 18; X1 and X2 each independently represent a single bond, -O-, -COO- or-OCO-; L1 represents -COO- or -OCO-; L2 represents-CH2CH2COO- or -CH2CH2OCO-; and Y1, Y2 and Y3 each independently represent a hydrogen atom, an alkyl group having 1 to 7 carbon atoms, an alkoxy group having 1 to 7 carbon atoms, an alkanoyl group having 2 to 7 carbon atoms, a cyano group or a halogen atom. Also disclosed are a polymerizable liquid crystal composition containing the compound, and an optically anisotropic medium produced from the composition.

POLYMERIZABLE COMPOSITION SHOWING LIQUID-CRYSTAL PHASE AND OPTICALLY ANISOTROPIC OBJECT MADE WITH THE SAME

An object of the present invention is to provide a polymerizable liquid crystal composition incorporating a polymerizable liquid crystal compound which displays a low nematic phase temperature, displays excellent compatibility with other polymerizable liquid crystal compounds, and furthermore yields a product following polymerization, of good transparency and high mechanical strength. A polymerizable composition is provided which displays a liquid crystal phase, and moreover incorporates a liquid crystal backbone with two or more ring structures and a compound with a partial structure represented by the general formulaP-S-A-D-E- [wherein P1 represents a polymerizable functional group; S1 represents -(CH2)w-, - O(CH2)w-, -(CH2)wO-, -(CH2)wC(=O)O-, -(CH2)wOC(=O)-, -C(=O)O(CH2)w- or - OC(=O)(CH2)w- (w: 1 to 20); A1 and E1 each represent a hydrocarbon ring or a hetero ring, although E1 is a ring incorporated within the liquid crystal backbone; and D1 represents - C(=O)-O-(CH2)m-O-, -O(CH2)m-O-C(=O)-, -O-C(=O)-(CH2)m-O-, or -O(CH2)m-C(=O)-O- (m: 1 to 15)].